tiprankstipranks
Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
US Market
ZBIO
Zenas BioPharma, Inc.
RESEARCH TOOLSreports
Want to see ZBIO full AI Analyst Report?

Zenas BioPharma, Inc. (ZBIO) Stock Forecast & Price Target

313 Followers
See the Price Targets and Ratings of:

ZBIO Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Zenas
BioPharma, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ZBIO Stock 12 Month Forecast

Average Price Target

$43.67
▲(100.12% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Zenas BioPharma, Inc. in the last 3 months. The average price target is $43.67 with a high forecast of $55.00 and a low forecast of $22.00. The average price target represents a 100.12% change from the last price of $21.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","20":"$20","32":"$32","44":"$44","56":"$56"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,20,32,44,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.36,22.10153846153846,24.84307692307692,27.584615384615383,30.326153846153844,33.067692307692305,35.809230769230766,38.550769230769234,41.29230769230769,44.033846153846156,46.77538461538461,49.51692307692308,52.25846153846154,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.36,21.229743589743588,23.099487179487177,24.96923076923077,26.838974358974358,28.708717948717947,30.57846153846154,32.44820512820513,34.31794871794872,36.1876923076923,38.057435897435894,39.92717948717949,41.79692307692308,{"y":43.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.36,19.563076923076924,19.766153846153845,19.96923076923077,20.17230769230769,20.375384615384615,20.57846153846154,20.78153846153846,20.984615384615385,21.18769230769231,21.39076923076923,21.593846153846155,21.796923076923076,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.56,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.36,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$55.00Average Price Target$43.67Lowest Price Target$22.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ZBIO
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$44
Buy
101.65%
Upside
Reiterated
05/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on ZBIO
David Nierengarten
Wedbush
Wedbush
$45
Buy
106.23%
Upside
Reiterated
05/14/26
Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)
Morgan Stanley Analyst forecast on ZBIO
Judah Frommer
Morgan Stanley
Morgan Stanley
$21→$22
Hold
0.82%
Upside
Reiterated
05/14/26
Zenas BioPharma price target raised to $22 from $21 at Morgan StanleyZenas BioPharma price target raised to $22 from $21 at Morgan Stanley
Citi Analyst forecast on ZBIO
Yigal Nochomovitz
Citi
Citi
$41
Buy
87.90%
Upside
Reiterated
05/13/26
Citi opens 'upside 30-day catalyst watch' on Zenas BioPharmaCiti opens 'upside 30-day catalyst watch' on Zenas BioPharma
Evercore ISI Analyst forecast on ZBIO
Cory Kasimov
Evercore ISI
Evercore ISI
$55
Buy
152.06%
Upside
Reiterated
03/17/26
Analysts' Top Healthcare Picks: Eton Pharmaceuticals (ETON), Zenas BioPharma, Inc. (ZBIO)
Guggenheim Analyst forecast on ZBIO
Yatin Suneja
Guggenheim
Guggenheim
$45→$55
Buy
152.06%
Upside
Reiterated
03/16/26
Guggenheim Remains a Buy on Zenas BioPharma, Inc. (ZBIO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ZBIO
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$44
Buy
101.65%
Upside
Reiterated
05/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on ZBIO
David Nierengarten
Wedbush
Wedbush
$45
Buy
106.23%
Upside
Reiterated
05/14/26
Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)
Morgan Stanley Analyst forecast on ZBIO
Judah Frommer
Morgan Stanley
Morgan Stanley
$21→$22
Hold
0.82%
Upside
Reiterated
05/14/26
Zenas BioPharma price target raised to $22 from $21 at Morgan StanleyZenas BioPharma price target raised to $22 from $21 at Morgan Stanley
Citi Analyst forecast on ZBIO
Yigal Nochomovitz
Citi
Citi
$41
Buy
87.90%
Upside
Reiterated
05/13/26
Citi opens 'upside 30-day catalyst watch' on Zenas BioPharmaCiti opens 'upside 30-day catalyst watch' on Zenas BioPharma
Evercore ISI Analyst forecast on ZBIO
Cory Kasimov
Evercore ISI
Evercore ISI
$55
Buy
152.06%
Upside
Reiterated
03/17/26
Analysts' Top Healthcare Picks: Eton Pharmaceuticals (ETON), Zenas BioPharma, Inc. (ZBIO)
Guggenheim Analyst forecast on ZBIO
Yatin Suneja
Guggenheim
Guggenheim
$45→$55
Buy
152.06%
Upside
Reiterated
03/16/26
Guggenheim Remains a Buy on Zenas BioPharma, Inc. (ZBIO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zenas BioPharma, Inc.

3 Months
Matthew CaufieldH.C. Wainwright
Success Rate
5/11 ratings generated profit
45%
Average Return
+10.38%
Copying Matthew Caufield's trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +10.38% per trade.
1 Year
Matthew CaufieldH.C. Wainwright
Success Rate
6/11 ratings generated profit
55%
Average Return
+45.29%
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +45.29% per trade.
2 Years
Matthew CaufieldH.C. Wainwright
Success Rate
6/11 ratings generated profit
55%
Average Return
+23.75%
Copying Matthew Caufield's trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +23.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZBIO Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
7
10
14
8
8
Buy
9
5
0
0
0
Hold
1
1
2
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
16
16
10
11
In the current month, ZBIO has received 8 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ZBIO average Analyst price target in the past 3 months is 43.67.
Each month's total comprises the sum of three months' worth of ratings.

ZBIO Financial Forecast

ZBIO Earnings Forecast

Next quarter’s earnings estimate for ZBIO is -$1.12 with a range of -$1.46 to -$0.12. The previous quarter’s EPS was -$1.46. ZBIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ZBIO has Performed in-line its overall industry.
Next quarter’s earnings estimate for ZBIO is -$1.12 with a range of -$1.46 to -$0.12. The previous quarter’s EPS was -$1.46. ZBIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ZBIO has Performed in-line its overall industry.

ZBIO Sales Forecast

Next quarter’s sales forecast for ZBIO is $15.00M with a range of $0.00 to $75.00M. The previous quarter’s sales results were $0.00. ZBIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ZBIO has Performed in-line its overall industry.
Next quarter’s sales forecast for ZBIO is $15.00M with a range of $0.00 to $75.00M. The previous quarter’s sales results were $0.00. ZBIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ZBIO has Performed in-line its overall industry.

ZBIO Stock Forecast FAQ

What is ZBIO’s average 12-month price target, according to analysts?
Based on analyst ratings, Zenas BioPharma, Inc.’s 12-month average price target is 43.67.
    What is ZBIO’s upside potential, based on the analysts’ average price target?
    Zenas BioPharma, Inc. has 100.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ZBIO a Buy, Sell or Hold?
          Zenas BioPharma, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Zenas BioPharma, Inc.’s price target?
            The average price target for Zenas BioPharma, Inc. is 43.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $55.00 ,the lowest forecast is $22.00. The average price target represents 100.12% Increase from the current price of $21.82.
              What do analysts say about Zenas BioPharma, Inc.?
              Zenas BioPharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of ZBIO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.